Bicara Therapeutics Inc. (BCAX)
(Delayed Data from NSDQ)
$10.20 USD
0.00 (0.00%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $10.16 -0.04 (-0.39%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BCAX 10.20 0.00(0.00%)
Will BCAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BCAX based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BCAX
Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board | BCAX Stock News
FMR LLC's Strategic Acquisition of Bicara Therapeutics Inc Shares
FMR LLC Reduces Stake in Bicara Therapeutics Inc: A Strategic Portfolio Adjustment
Bicara Therapeutics Elects New Directors at Annual Meeting
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus